Land: Nya Zeeland
Språk: engelska
Källa: Medsafe (Medicines Safety Authority)
Duloxetine hydrochloride 33.7mg equivalent to duloxetine base 30 mg;
Eli Lilly and Company (NZ) Limited
Duloxetine hydrochloride 33.7 mg (equivalent to duloxetine base 30 mg)
30 mg
Modified release capsule
Active: Duloxetine hydrochloride 33.7mg equivalent to duloxetine base 30 mg Excipient: Ammonia solution Colour mixture White DDB8257W Gelatin Hypromellose Hypromellose acetate succinate Indigo carmine Ink Purified talc Sodium laurilsulfate Sucrose Sugar spheres Titanium dioxide Triethyl citrate
Blister pack, PVC/PE/Aclar x 7 sample pack, 7 capsules
Prescription
Prescription
Lilly del Caribe Inc
Package - Contents - Shelf Life: Blister pack, PVC/PE/Aclar x 7 sample pack - 7 capsules - 36 months from date of manufacture stored at or below 30°C - Blister pack, PVC/Polyethylene/Aclar x 28 - 28 capsules - 36 months from date of manufacture stored at or below 30°C
2003-07-31
Cymbalta NZ Datasheet Version 4.0 May 2011 DATA SHEET CYMBALTA ® Duloxetine capsules, 30 mg and 60 mg. PRESENTATION CYMBALTA 30 mg capsules have opaque white bodies and opaque blue caps. CYMBALTA 60 mg capsules have opaque green bodies and opaque blue caps. CYMBALTA is a delayed-release formulation for oral administration. CYMBALTA 30 mg and 60 mg capsules contains enteric-coated pellets of duloxetine hydrochloride equivalent to 30 mg and 60 mg of duloxetine, respectively. Enteric coating prevents degradation of the medicine within the acidic environment of the stomach. USES _ACTIONS _ Pharmacotherapeutic group: medicines used for the treatment of depression, anxiety and neuropathic pain. Duloxetine is a combined serotonin (5-HT) and noradrenaline (NA) reuptake inhibitor. It weakly inhibits dopamine reuptake with no significant affinity for histaminergic, dopaminergic, cholinergic and adrenergic receptors. Duloxetine dose-dependently increased extracellular levels of serotonin and noradrenaline in various brain areas of animals. _PHARMACODYNAMICS _ Neurochemical and behavioural studies in laboratory animals showed an enhancement of both serotonin and noradrenaline neurotransmission in the CNS. Duloxetine also normalised pain thresholds in several preclinical models of neuropathic and inflammatory pain and attenuated pain behaviour in a model of persistent pain. The presumed mechanism of action of duloxetine in the treatment of depression is thought to be due to its inhibition of neuronal uptake of serotonin and noradrenaline, and a resultant increase in serotonergic and noradrenergic neurotransmission in the CNS. The pain inhibitory action of duloxetine is believed to be a result of potentiation of descending inhibitory pain pathways within the central nervous system. _CLINICAL TRIALS _ Acute t Läs hela dokumentet